In addition to CD19 deficiency or low expression levels, the barriers of an effective CAR T-cell therapy also include severe life-threatening toxicity, such as cytokine release syndrome (CRS), the most common type of toxicity [46,47], modest anti-tumor activity, antigen escape, restricted CAR T-cell trafficking, and limited tumor infiltration [25]. Here, CD19 is linked to neoplasm.